ABEO insider plans sale of 14,814 shares

Abeona Therapeutics insider plans Rule 144 stock sale.

Accepted by SEC EDGAR 02/02/2026 - 04:58 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Abeona Therapeutics insider plans Rule 144 stock sale. A holder has filed to sell 14,814 shares of Abeona Therapeutics common stock, with an aggregate market value of $75,412.00, through Stifel Nicolaus on the Nasdaq exchange around 02/02/2026.

The shares relate to equity compensation: 36,101 common shares were acquired on 01/31/2026 via restricted stock units granted by the issuer and paid in equity. Common shares outstanding were 54,191,361 at the time of the notice.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for ABEO disclose?

The Form 144 for ABEO discloses a planned sale of 14,814 common shares with an aggregate market value of $75,412.00. The sale is to be executed through Stifel Nicolaus on Nasdaq around 02/02/2026 under Rule 144 resale provisions.

How many ABEO shares are planned to be sold under this Form 144?

The Form 144 indicates a planned sale of 14,814 Abeona Therapeutics common shares. These shares have an aggregate market value of $75,412.00 at the time of the notice and are to be sold on the Nasdaq market through Stifel Nicolaus.

How were the ABEO shares in this Form 144 acquired?

The ABEO shares were acquired on 01/31/2026 through restricted stock units granted by the issuer. A total of 36,101 common shares were received as equity compensation, rather than for cash, before the holder filed the Rule 144 sale notice.

What is the market value of ABEO stock covered by this Form 144?

The Form 144 lists an aggregate market value of $75,412.00 for the 14,814 ABEO common shares to be sold. This value reflects the market price at the time of the notice for the proposed Rule 144 transaction through Stifel Nicolaus on Nasdaq.

How many ABEO shares were outstanding when this Form 144 was filed?

At the time of the Form 144 notice, Abeona Therapeutics had 54,191,361 common shares outstanding. This figure provides context for the planned sale of 14,814 shares, indicating the sale involves a small portion of the company’s total share count.

Which broker and exchange are used in the ABEO Form 144 sale?

The ABEO Form 144 names Stifel Nicolaus & Company Inc. as broker and Nasdaq as the securities exchange. The notice specifies that the 14,814 common shares are expected to be sold on or about 02/02/2026 through this broker on Nasdaq.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001857854
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ABEONA THERAPEUTICS INC.
SEC File Number	001-15771
Address of Issuer	6555 CARNEGIE AVE, 4TH FLOOR CLEVELAND OHIO 44103
Phone	646-813-4701
Name of Person for Whose Account the Securities are To Be Sold	Wuchterl Donald A.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102	14814	75412.00	54191361	02/02/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/31/2026	Restricted Stock Units	Issuer			36101	01/31/2026	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	These shares were sold to cover tax obligations pursuant to an RSA vesting event.
Date of Notice	02/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Luca Lotito, as a duly authorized representative of STIFEL, as attorney-in-fact for Donald Wuchterl
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)